Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice [Yahoo! Finance]
Pelthos Therapeutics Inc. (PTHS)
Company Research
Source: Yahoo! Finance
Xeglyze is a novel, FDA-approved prescription medication indicated for the topical treatment of head lice infestation in patients 6 months of age and older DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has acquired Xeglyze® (abametapir) from Hatchtech Pty Ltd., an Australian biotech company, for $1.8 million. Xeglyze is a pediculicide indicated for the topical treatment of head lice infestation in patients 6 months of age and older. The prescription medication was approved by the U.S. Food and Drug Administration (“FDA”) in July 2020. The acquisition will provide Pelthos with the ability to commercialize Xeglyze worldwide, and there are no future milestone, royalty or other payments owed to Hatchtech. “This acquisition allows us to add another complementary FDA-approved product to ou
Show less
Read more
Impact Snapshot
Event Time:
PTHS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTHS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTHS alerts
High impacting Pelthos Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
PTHS
News
- Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology FinanceGlobeNewswire
- Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head LiceGlobeNewswire
- Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew EinhornGlobeNewswire
- Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript [Seeking Alpha]Seeking Alpha
- Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%GlobeNewswire
PTHS
Earnings
- 11/13/25 - Miss
PTHS
Sec Filings
- 1/13/26 - Form 8-K
- 1/12/26 - Form 8-K
- 1/2/26 - Form 8-K
- PTHS's page on the SEC website